Skin-directed radiation therapy for cutaneous lymphoma

Skin-directed radiation therapy for cutaneous lymphoma: The Mayo Clinic experience.:

Related Articles

Skin-directed radiation therapy for cutaneous lymphoma: The Mayo Clinic experience.

J Am Acad Dermatol. 2020 Mar;82(3):634-641

Authors: King BJ, Lester SC, Tolkachjov SN, Davis MDP, Gibson LE, Martenson JA

Abstract

BACKGROUND: Focal or total skin radiation therapy can be used to treat mild to refractory cutaneous T-cell lymphoma.

OBJECTIVE: To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma.

METHODS: Retrospective, single-institution review of outcomes for skin-directed radiation therapy.

RESULTS: Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation.

LIMITATIONS: Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number).

CONCLUSIONS: Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.



PMID: 31344376 [PubMed - indexed for MEDLINE]